{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:05:13Z","timestamp":1787504713409,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40263-019-00606-6","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T11:39:13Z","timestamp":1550835553000},"page":"239-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-6341","authenticated-orcid":false,"given":"Abdelrahman","family":"Elshafay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6846-8369","authenticated-orcid":false,"given":"Truong Hong","family":"Hieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-5078","authenticated-orcid":false,"given":"Mohamed Fahmy","family":"Doheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Attia Mohamed","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Fathi","family":"ELdoadoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Keturah","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Abo-elghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-1777","authenticated-orcid":false,"given":"Kenji","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-9440","authenticated-orcid":false,"given":"Nguyen Tien","family":"Huy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"issue":"6","key":"606_CR1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejpn.2018.08.009","volume":"22","author":"EF Tizzano","year":"2018","unstructured":"Tizzano EF, Zafeiriou D. Prenatal aspects in spinal muscular atrophy: from early detection to early presymptomatic intervention. Eur J Paediatr Neurol 2018;22(6):944\u201350.","journal-title":"Eur J Paediatr Neurol"},{"issue":"8","key":"606_CR2","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","volume":"55","author":"A Govoni","year":"2018","unstructured":"Govoni A, et al. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol. 2018;55(8):6307\u201318.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"606_CR3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"606_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000110905","volume":"11","author":"ML Mostacciuolo","year":"1992","unstructured":"Mostacciuolo ML, et al. Epidemiology of spinal muscular atrophies in a sample of the Italian population. Neuroepidemiology. 1992;11(1):34\u20138.","journal-title":"Neuroepidemiology"},{"issue":"3","key":"606_CR5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","volume":"15","author":"B Wirth","year":"2000","unstructured":"Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228\u201337.","journal-title":"Hum Mutat"},{"issue":"9","key":"606_CR6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4155\/fmc.14.63","volume":"6","author":"MD Howell","year":"2014","unstructured":"Howell MD, Singh NN, Singh RN. Advances in therapeutic development for spinal muscular atrophy. Future Med Chem. 2014;6(9):1081\u201399.","journal-title":"Future Med Chem"},{"issue":"8","key":"606_CR7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"BS Russman","year":"2007","unstructured":"Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22(8):946\u201351.","journal-title":"J Child Neurol"},{"issue":"3","key":"606_CR8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.23995","volume":"74","author":"WD Arnold","year":"2013","unstructured":"Arnold WD, Burghes AHM. Spinal muscular atrophy: development and implementation of potential treatments. Ann Neurol. 2013;74(3):348\u201362.","journal-title":"Ann Neurol"},{"issue":"1","key":"606_CR9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"3","key":"606_CR10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jmg.29.3.171","volume":"29","author":"J Melki","year":"1992","unstructured":"Melki J, et al. Prenatal prediction of Werdnig-Hoffmann disease using linked polymorphic DNA probes. J Med Genet. 1992;29(3):171\u20134.","journal-title":"J Med Genet"},{"issue":"6266","key":"606_CR11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","volume":"344","author":"L Brzustowicz","year":"1990","unstructured":"Brzustowicz L, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q1 1.2\u201313.3. Nature. 1990;344(6266):540.","journal-title":"Nature."},{"issue":"10","key":"606_CR12","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/4.10.1927","volume":"4","author":"E Hahnen","year":"1995","unstructured":"Hahnen E, et al. Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet. 1995;4(10):1927\u201333.","journal-title":"Hum Mol Genet"},{"issue":"10063","key":"606_CR13","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326.","journal-title":"Lancet"},{"issue":"4","key":"606_CR14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nn.4508","volume":"20","author":"DR Corey","year":"2017","unstructured":"Corey DR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci. 2017;20(4):497.","journal-title":"Nat Neurosci"},{"issue":"9","key":"606_CR15","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","volume":"14","author":"LE Kernochan","year":"2005","unstructured":"Kernochan LE, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet. 2005;14(9):1171\u201382.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"606_CR16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35\u00a0years of clinical experience. CNS Drugs. 2002;16(10):695\u2013714.","journal-title":"CNS Drugs"},{"issue":"2","key":"606_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2165\/00023210-199402020-00007","volume":"2","author":"JA Balfour","year":"1994","unstructured":"Balfour JA, Bryson HM. Valproic acid. CNS Drugs. 1994;2(2):144\u201373.","journal-title":"CNS Drugs"},{"issue":"10","key":"606_CR18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","volume":"16","author":"W L\u00f6scher","year":"2002","unstructured":"L\u00f6scher W. Basic pharmacology of valproate. CNS Drugs. 2002;16(10):669\u201394.","journal-title":"CNS Drugs"},{"issue":"5","key":"606_CR19","first-page":"647","volume":"54","author":"CJ Sumner","year":"2003","unstructured":"Sumner CJ, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 2003;54(5):647\u201354.","journal-title":"Ann Neurol Off J Am Neurol Assoc Child Neurol Soc"},{"issue":"19","key":"606_CR20","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","volume":"12","author":"L Brichta","year":"2003","unstructured":"Brichta L, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003;12(19):2481\u20139.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"606_CR21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.nbd.2006.07.004","volume":"24","author":"L-K Tsai","year":"2006","unstructured":"Tsai L-K, et al. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol Dis. 2006;24(2):286\u201395.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"606_CR22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","volume":"67","author":"CC Weihl","year":"2006","unstructured":"Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy. Neurology. 2006;67(3):500\u20131.","journal-title":"Neurology"},{"issue":"12","key":"606_CR23","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/j.1468-1331.2007.01992.x","volume":"14","author":"LK Tsai","year":"2007","unstructured":"Tsai LK, et al. Valproic acid treatment in six patients with spinal muscular atrophy. Eur J Neurol. 2007;14(12):e8\u20139.","journal-title":"Eur J Neurol"},{"issue":"339","key":"606_CR24","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"21","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;21(339):b2700.","journal-title":"BMJ"},{"key":"606_CR25","volume-title":"Statistical methods for rates and proportions","author":"JL Fleiss","year":"2013","unstructured":"Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions, 3rd edn. Hoboken: John Wiley & Sons; 2013.","edition":"3"},{"issue":"1","key":"606_CR26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"key":"606_CR27","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"606_CR28","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"606_CR29","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions, vol. 4. New York: Wiley; 2011."},{"issue":"1","key":"606_CR30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.","journal-title":"BMC Med Res Methodol"},{"key":"606_CR31","volume-title":"Empirical assessment of within-arm correlation imputation in trials of continuous outcomes","author":"EM Balk","year":"2012","unstructured":"Balk EM, et al. AHRQ methods for effective health care. In: Empirical assessment of within-arm correlation imputation in trials of continuous outcomes. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012."},{"issue":"6","key":"606_CR32","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","volume":"59","author":"L Brichta","year":"2006","unstructured":"Brichta L, et al. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol. 2006;59(6):970\u20135.","journal-title":"Ann Neurol"},{"issue":"1","key":"606_CR33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-11-36","volume":"11","author":"IA Darbar","year":"2011","unstructured":"Darbar IA, et al. Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol. 2011;11(1):36.","journal-title":"BMC Neurol"},{"issue":"2","key":"606_CR34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.23904","volume":"49","author":"JT Kissel","year":"2014","unstructured":"Kissel JT, et al. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve. 2014;49(2):187\u201392.","journal-title":"Muscle Nerve"},{"issue":"7","key":"606_CR35","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","volume":"6","author":"JT Kissel","year":"2011","unstructured":"Kissel JT, et al. SMA carni-VAL trial part II: a prospective, single-armed trial of l-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One. 2011;6(7):e21296.","journal-title":"PLoS One"},{"issue":"8","key":"606_CR36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.2009.200253","volume":"82","author":"S Piepers","year":"2011","unstructured":"Piepers S, et al. Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid. J Neurol Neurosurg Psychiatry. 2011;82(8):850\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"606_CR37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JND-150081","volume":"2","author":"SR Renusch","year":"2015","unstructured":"Renusch SR, et al. Spinal Muscular Atrophy biomarker measurements from blood samples in a clinical trial of valproic acid in ambulatory adults. J Neuromuscul Dis. 2015;2(2):119\u201330.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"606_CR38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ncn3.140","volume":"3","author":"T Saito","year":"2015","unstructured":"Saito T, et al. A Study of valproic acid for patients with spinal muscular atrophy. Neurol Clin Neurosci. 2015;3(2):49\u201357.","journal-title":"Neurol Clin Neurosci"},{"issue":"8","key":"606_CR39","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","volume":"5","author":"KJ Swoboda","year":"2010","unstructured":"Swoboda KJ, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010;5(8):e12140.","journal-title":"PLoS One"},{"issue":"5","key":"606_CR40","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","volume":"4","author":"KJ Swoboda","year":"2009","unstructured":"Swoboda KJ, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009;4(5):e5268.","journal-title":"PLoS One"},{"issue":"2","key":"606_CR41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mus.25776","volume":"57","author":"KJ Krosschell","year":"2018","unstructured":"Krosschell KJ, et al. Clinical trial of l-carnitine and valproic acid in spinal muscular atrophy type I. Muscle Nerve. 2018;57(2):193\u20139.","journal-title":"Muscle Nerve"},{"issue":"2","key":"606_CR42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mus.22040","volume":"44","author":"KJ Krosschell","year":"2011","unstructured":"Krosschell KJ, et al. Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy. Muscle Nerve. 2011;44(2):246\u201351.","journal-title":"Muscle Nerve"},{"issue":"5","key":"606_CR43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","volume":"54","author":"CJ Sumner","year":"2003","unstructured":"Sumner CJ, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54(5):647\u201354.","journal-title":"Ann Neurol"},{"issue":"11","key":"606_CR44","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1111\/j.1460-9568.2004.03765.x","volume":"20","author":"F Sugai","year":"2004","unstructured":"Sugai F, et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci. 2004;20(11):3179\u201383.","journal-title":"Eur J Neurosci"},{"key":"606_CR45","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1021\/ed051p652","volume":"51","author":"A Bezkorovainy","year":"1974","unstructured":"Bezkorovainy A. Carnosine, carnitine, and Vladimir Gulevich. J Chem Educ. 1974;51:652\u20134.","journal-title":"J Chem Educ."},{"key":"606_CR46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/bjc.1995.482","volume":"72","author":"BK Winter","year":"1995","unstructured":"Winter BK, Fiskum G, Gallo LL. Effects of l-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer. 1995;72:1173\u20139.","journal-title":"Br J Cancer."},{"key":"606_CR47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15563650902752376","volume":"47","author":"PE Lheureux","year":"2009","unstructured":"Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila). 2009;47:101\u201311.","journal-title":"Clin Toxicol (Phila)"},{"key":"606_CR48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","volume":"31","author":"MF Silva","year":"2008","unstructured":"Silva MF, Aires CC, Luis PB. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation. A review. J Inherit Metabol Dis. 2008;31:205\u201316.","journal-title":"J Inherit Metabol Dis"},{"issue":"3","key":"606_CR49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00002060-200005000-00002","volume":"79","author":"S-W Kang","year":"2000","unstructured":"Kang S-W, Bach JR. Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease. Am J Phys Med Rehabil. 2000;79(3):222\u20137.","journal-title":"Am J Phys Med Rehabil"},{"issue":"3","key":"606_CR50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/1531-8249(199903)45:3<337::AID-ANA9>3.0.CO;2-U","volume":"45","author":"TO Crawford","year":"1999","unstructured":"Crawford TO, et al. Abnormal fatty acid metabolism in childhood spinal muscular atrophy. Ann Neurol. 1999;45(3):337\u201343.","journal-title":"Ann Neurol"},{"issue":"1","key":"606_CR51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0887-8994(94)00100-G","volume":"12","author":"I Tein","year":"1995","unstructured":"Tein I, et al. Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)? Pediatr Neurol. 1995;12(1):21\u201330.","journal-title":"Pediatr Neurol"},{"issue":"8378","key":"606_CR52","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(84)92209-8","volume":"323","author":"D Coulter","year":"1984","unstructured":"Coulter D. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet. 1984;323(8378):689.","journal-title":"Lancet"},{"issue":"2","key":"606_CR53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/hmg\/dds437","volume":"22","author":"L Garbes","year":"2013","unstructured":"Garbes L, et al. VPA response in SMA is suppressed by the fatty acid translocase CD36. Hum Mol Genet. 2013;22(2):398\u2013407.","journal-title":"Hum Mol Genet"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00606-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00606-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:56:01Z","timestamp":1585893361000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00606-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00606-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"22 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors, AE,\u00a0THH, MFD, MAMK, MFE, SKH, HA, KH, and NTH, declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}